- Home
- HTH vs IMCR Comparison
HTH vs IMCR Comparison
Compare HTH & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTH
- IMCR
- Stock Information
- Founded
- HTH 1998
- IMCR 2008
- Country
- HTH United States
- IMCR United Kingdom
- Employees
- HTH N/A
- IMCR N/A
- Industry
- HTH Major Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HTH Finance
- IMCR Health Care
- Exchange
- HTH Nasdaq
- IMCR Nasdaq
- Market Cap
- HTH 1.9B
- IMCR 1.6B
- IPO Year
- HTH 2004
- IMCR 2021
- Fundamental
- Price
- HTH $30.77
- IMCR $35.00
- Analyst Decision
- HTH Hold
- IMCR Buy
- Analyst Count
- HTH 2
- IMCR 10
- Target Price
- HTH $33.00
- IMCR $58.13
- AVG Volume (30 Days)
- HTH 468.9K
- IMCR 383.2K
- Earning Date
- HTH 07-24-2025
- IMCR 08-07-2025
- Dividend Yield
- HTH 2.33%
- IMCR N/A
- EPS Growth
- HTH 15.07
- IMCR N/A
- EPS
- HTH 1.97
- IMCR N/A
- Revenue
- HTH $1,208,822,000.00
- IMCR $333,581,000.00
- Revenue This Year
- HTH N/A
- IMCR $26.82
- Revenue Next Year
- HTH $1.36
- IMCR $8.15
- P/E Ratio
- HTH $15.71
- IMCR N/A
- Revenue Growth
- HTH 2.13
- IMCR 25.75
- 52 Week Low
- HTH $26.67
- IMCR $23.15
- 52 Week High
- HTH $35.32
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- HTH 52.06
- IMCR 59.78
- Support Level
- HTH $30.92
- IMCR $32.20
- Resistance Level
- HTH $32.16
- IMCR $35.75
- Average True Range (ATR)
- HTH 0.53
- IMCR 1.31
- MACD
- HTH 0.04
- IMCR 0.28
- Stochastic Oscillator
- HTH 50.34
- IMCR 84.94
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.